Immunome, Inc. (NASDAQ:IMNM) Insider Robert Lechleider Acquires 15,805 Shares

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider acquired 15,805 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares of the company’s stock, valued at $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Price Performance

Immunome stock opened at $11.53 on Wednesday. The stock has a market cap of $719.70 million, a price-to-earnings ratio of -1.42 and a beta of 1.82. The firm has a 50-day moving average of $12.49 and a two-hundred day moving average of $13.55. Immunome, Inc. has a 1 year low of $6.93 and a 1 year high of $30.96.

Institutional Trading of Immunome

Large investors have recently modified their holdings of the company. Barclays PLC increased its holdings in Immunome by 125.9% during the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after purchasing an additional 59,016 shares during the period. Geode Capital Management LLC grew its position in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after buying an additional 144,557 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Immunome during the 3rd quarter worth $363,000. Wellington Management Group LLP increased its stake in shares of Immunome by 137.1% during the third quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock valued at $2,057,000 after buying an additional 81,354 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of Immunome by 22.2% in the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after acquiring an additional 85,580 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on IMNM. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Piper Sandler dropped their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Stephens assumed coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $28.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.